Damien

I believe the cost for long term treatment set against the statistical likelihood of survival/reoccurrence is one of the key measurements NICE (the NHS don't do this part) take into account. It will be a question of how big an increase do you get in average survival vs the cost.

A lot of the time the drug offers questionable, if any, improvement at a much higher cost so it gets rejected and gets met by headlines of how they're refusing a patient a drug that could save their life - the 'could' doing a lot of work in the headline.

If this is a dramatic increase though it will probably be approved. It's a question of saving lives in the end.